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Abstract
Dihydroartemisinin-piperaquine (DP) has demonstrated excellent efficacy for the
treatment and prevention of malaria in Uganda. However, resistance to both components
of this regimen has emerged in Southeast Asia. The efficacy of artemether-lumefantrine,
the first-line regimen to treat malaria in Uganda, has also been excellent, but continued
pressure may select for parasites with decreased sensitivity to lumefantrine. To gain
insight into current drug sensitivity patterns, ex vivo sensitivities were assessed and
genotypes previously associated with altered drug sensitivity were characterized for 58
isolates collected in Tororo, Uganda from subjects presenting in 2016 with malaria from
the community or as part of a clinical trial comparing DP chemoprevention regimens.
Compared to community isolates, those from trial subjects had lower sensitivities to the
aminoquinolines chloroquine, monodesethyl amodiaquine, and piperaquine, and greater
sensitivities to lumefantrine and mefloquine, consistent with DP selection pressure.
Compared to results for isolates from 2010-13, sensitivities of 2016 community isolates
to chloroquine, amodiaquine, and piperaquine improved (geometric mean IC50s 248, 76.9,
and 19.1 nM in 2010-13 and 33.4, 14.9, and 7.5 nM in 2016, respectively, P<0.001 for all
comparisons), sensitivity to lumefantrine decreased (IC50 3.0 nM in 2010-13 and 5.4 nM
in 2016, P<0.001), and sensitivity to dihydroartemisinin was unchanged (IC50 1.4 nM).
These changes were accompanied by decreased prevalence of transporter mutations
associated with aminoquinoline resistance and low prevalence of polymorphisms recently
associated with resistance to artemisinins or piperaquine. Antimalarial drug sensitivities
are changing in Uganda, but novel genotypes associated with DP treatment failure in Asia
are not prevalent.
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Background
Malaria Burden
Malaria has been evolving with humans for thousands of years, yet it remains a
serious public health concern. According to the World Health Organization (WHO), there
were approximately 216 million new cases and approximately 445,000 deaths from
malaria worldwide in 2016. Eighty percent of the worldwide cases and 91% of the deaths
occurred in Sub-Saharan Africa, with 99% of the estimated cases caused by Plasmodium
falciparum, the most lethal of the human malaria species. Pregnant women and children
under the age of five are the primary groups affected by malaria (1). Unfortunately, the
majority of malaria cases are located in developing countries, where lack of resources
hinders eradication efforts.

Human Malaria Life Cycle
Malaria is a disease caused by single-cell protozoa from the phylum Apicomplexa,
genus Plasmodium. There are five different species of Plasmodium that can infect and
cause malaria in humans – P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi,
all of which require a mosquito host for sexual reproduction and a human host for asexual
reproduction (Figure 1). Only female Anopheles species are suitable mosquito hosts for
human malaria species. Once inside a mosquito the malaria gametocytes develop into
gametes. A microgamete fuses with a macrogamete to produce a zygote. The zygote
develops into a motile ookinete that penetrates the mosquito’s gut wall and develops into
an oocyst on the hemocoel side of the gut. Via mitosis and meiosis, the oocyst turns into
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sporoblasts, haploid nucleated masses, that divide to form motile sporozoites (2). The
sporozoites break out of the oocyst, travel to the mosquito’s salivary glands, and lead to
human infection when the mosquito takes a blood meal, injecting the sporozoites. The
entire development in the mosquito takes approximately 10-12 days.

Figure 1. The life cycle of human malaria species. The life cycle involves sexual
reproduction in a female Anopheles mosquito and asexual replication in a human host.
Image taken with permission from the CDC – DPDx Public Health Image Library (3).

To initiate the human phase of the life cycle, an infected mosquito injects
sporozoites via its saliva into the bloodstream while taking a blood meal. After the first
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twenty-four hours in the blood stream, the sporozoites migrate to the liver where they
invade hepatocytes in a ligand-receptor-mediated fashion (4). Once inside the hepatocyte,
the malaria parasite goes through asexual reproduction, forming thousands of merozoites
that exit the liver cells in about seven to ten days, depending on the species of malaria.
The merozoites leave the liver and invade erythrocytes to initiate the asexual blood stage
infection. Inside the erythrocyte, the parasite goes through a round of asexual replication
that takes approximately 48 hours for P. falciparum and results in the rupture of the
infected red blood cell, releasing up to 32 newly formed merozoites that subsequently
infect new erythrocytes. The erythrocytic cycle is responsible for all clinical
manifestations of malaria (5) and persists indefinitely. Some erythrocytic parasites
develop into the sexual stages, the microgametocyte and the macrogametocyte. When a
mosquito takes a blood meal from a human host that contains these gametocytes, the
Plasmodium life cycle enters the invertebrate, sexual stage.

Clinical Falciparum Malaria
Patients with malaria can have varying degrees of symptoms, ranging from
asymptomatic to severe, life-threatening complications. In uncomplicated malaria,
patients exhibit nonspecific symptoms such as anemia, fever, malaise, headaches, body
aches, and nausea (5). However, complicated or severe malaria can have lethal
consequences because patients can develop metabolic acidosis, severe anemia, and
cerebral malaria. P. falciparum is the most dangerous human malaria species because of
its ability to cause complicated malaria by causing severe anemia and cytoadherance of
infected red blood cells to the brain, heart, lungs, liver, kidneys, and placenta (6).
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Even though the mechanism by which uncomplicated malaria progresses to
complicated malaria is not fully understood, the ability of P. falciparum-infected
erythrocytes to adhere to tissues appears to play a key role. Sequestration of infected red
blood cells in the placenta can lead to hazardous conditions for the fetus and mother
including maternal anemia, reduced birth weight, premature birth, and increased
mortality of the newborn. Additionally, sequestration of infected red blood cells in the
brain is hypothesized to play a role in cerebral malaria, which often leads to coma, brain
damage, and/or death (7). Because of the danger P. falciparum poses to human health, it
is imperative that useful, effective antimalarials are available for the treatment of the
disease.

Drug Resistant P. falciparum
It is essential to have potent, safe, and inexpensive antimalarials available for the
treatment of malaria. Chloroquine, an antimalarial that gained popularity in 1950, was a
game-changing drug for the treatment of malaria because it had minimal side effects, was
efficacious, and was affordable. However after only a decade of widespread use,
resistance originated from independent foci in Asia and South America that later spread
throughout the world, rendering the drug useless (8, 9). Resistance to chloroquine and the
structurally related drug amodiaquine, both of which are in the 4-aminoquinoline drug
class, has been linked to mutations in the Plasmodium falciparum chloroquine resistance
transporter (PfCRT) at position 76 and Plasmodium falciparum multi-drug resistance
transporter 1 (PfMDR1) at positions 86 and 1246, which are both transmembrane
proteins on the parasite digestive vacuole hypothesized to mediate the influx and efflux
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of drugs (8, 10). In an effort to find a useful replacement, artemisinin-based combination
therapies (ACTs) were developed (11).
Currently, the first line therapies for uncomplicated P. falciparum infections are
ACTs (12). Unlike chloroquine, the ACTs combine a fast acting artemisinin derivative
with a slow acting partner drug, such as piperaquine, lumefantrine, mefloquine,
amodiaquine, or pyronaridine, that work in combination to eradicate the malaria parasites
in a patient. The artemisinin derivative is very potent and fast acting, so it kills the
majority of the parasites in a patient’s blood stream quickly while the slow acting partner
drug with a longer half-life stays in the patient longer and kills any remaining parasites
(Figure 2) (13, 14). ACTs have proven to be efficacious and have a good safety record (1,
12).

Artemisinin

Drug Concentration
or
Parasite Density

New Infections

Partner Drug

Parasite Density

Time

Figure 2. Mechanism of action of ACTs. ACTs work by combining a fast acting
artemisinin derivative with a slow acting partner drug to effectively kill all the parasites
in a patient. Initially, the artemisinin kills the majority of the parasites in the patient and
the partner drug kills the surviving parasites. New infections may occur once the slowacting partner drug concentration drops to sub-therapeutic levels.
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Unfortunately, resistance to the artemisinin component of ACTs has developed in
Southeast Asia (15, 16). Clinical artemisinin resistance is defined as a delayed clearance
phenotype, meaning that it takes significantly longer for the drug to clear parasites. In a
region of Cambodia with artemisinin resistance, it took on average 36 more hours to clear
parasites with artesunate monotherapy compared to a region of Thailand without
artemisinin resistance (16). The delayed clearance phenotype has been linked to single
nucleotide polymorphisms (SNPs), specifically C580Y, R539T, Y493H, M476I, and
I543T, in the kelch propeller domain of the protein encoded by the kelch k13 gene (15, 17,
18). Because artemisinins are now failing in Southeast Asia, it is even more crucial to use
combination therapies for the treatment of malaria.
The partner drugs in ACTs can kill the parasites when the artemisinin fails, so
combination therapies are a useful way to prevent drug resistance from emerging. Two or
more drugs that target different biochemical pathways in the parasite would likely slow
down the acquisition of drug resistance. Nevertheless, with ACTs the risk of developing
resistance to the slow acting partner drug is serious if patients get re-infected during a
time when there are sub-therapeutic levels of the partner drug present in their blood (11)
(Figure 2). Additionally, now that artemisinin resistance is present in Southeast Asia,
there is even more selective pressure on the partner drugs, and currently, drug resistance
to the partner drugs piperaquine, mefloquine, and amodiaquine is present in Southeast
Asia (19-22).
Clinical dihydroartemisinin-piperaquine (DP) failure has recently developed in
Southeast Asia and has been associated with increased plasmepsin 2 copy number in two
studies and with an E415G encoding mutation in an exonuclease gene in one study (23,
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24). DP failure is especially concerning because it has been shown to have excellent
efficacy for the treatment of malaria and for malaria chemoprevention in both children
and pregnant women in Africa (25-29). DP works well as a chemoprevention therapy
because piperaquine has a long half-life (23 days [range 19-28 days] in adults and 14
days [range 10-18 days] in children (30)), which helps protect patients from new malaria
infections for a longer amount of time (Figure 2). Piperaquine, a bisquinoline, is an
interesting drug because it is structurally similar to the 4-aminoquinolines chloroquine
and amodiaquine, but its mechanism of action and selective pressures are not as well
understood as they are for the other 4-aminoquinolines.
Resistance to the partner drug mefloquine, an arylaminoalcohol, was first reported
in 1982 (31), five years after it was introduced, and has been associated with increased
pfmdr1 copy number in both in vitro and in vivo experiments (21, 32-34). Interestingly,
resistance to the partner drug lumefantrine, which is an arylaminoalcohol-containing
fluorene, has not been described to date. However similar to mefloquine, increased
pfmdr1 copy number has been associated with decreased sensitivity to lumefantrine (21,
32-34). Oppositely, an N86Y mutation in PfMDR1 has been shown to be associated with
increased sensitivity to both of these drugs (35). Even though the exact mechanism by
which these drugs act is uncertain, in vivo and in vitro studies have shown that decreased
sensitivity to both drugs is mediated by the wildtype genotype at position 76 in PfCRT
and positions 86 and 1246 in PfMDR1, which for the 4-aminoquinolines is associated
with increased sensitivity (35-40). The arylaminoalcohols and 4-aminoquinolines exert
opposite selective pressures on mediators of P. falciparum drug resistance.
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Antimalarial Use in Africa
Historically, chloroquine was used to treat uncomplicated malaria in Africa, but it
has been replaced by the ACTs artemether-lumefantrine (AL) and artesunateamodiaquine (ASAQ) in most African countries. These ACTs are highly efficacious in
Africa, with efficacy rates above 97% from 2010-2016 (1, 12). However, considering the
fact that the vast majority of the world’s malaria and falciparum malaria cases occur in
this region, it is pertinent to continue surveillance efforts to ensure the swift detection of
resistance if or when it develops in Africa to facilitate the subsequent change of drug
therapy policies.

Hypothesis and Rationale
The work contained in this thesis was focused on studying the phenotypic and
genotypic mechanisms of drug resistance present in clinical P. falciparum isolates from
the Tororo District of Uganda (Figure 3). The Tororo District, located in the Southeastern
part of Uganda, has a high burden of malaria and people were bitten by an average of 125
infective mosquitoes per year in 2011-2012 (41). Uganda recently widely implemented
AL as the national therapy for uncomplicated malaria after switching from chloroquine in
2006. Our group collected a large amount of ex vivo drug sensitivity data and genetic data
on P. falciparum clinical isolates from Tororo between 2010-2013 (40). Unsurprisingly
because clinical chloroquine resistance was widespread, the study showed that a large
proportion of P. falciparum isolates had decreased sensitivity to the 4-aminoquinolines
and a high prevalence of SNPs associated with resistance to the 4-aminoquinolines.
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When we returned to Tororo in 2016, we sought to study the current drug sensitivity
phenotypes and genotypes present in P. falciparum isolates from the same location in the
new setting of decreased chloroquine use and widespread AL use. We hypothesized that
parasites in 2016 would differ significantly from those studied between 2010-2013
because of the different drug therapies now used in the community.

Figure 3. Map of Uganda. The red star indicates the location of the study site Tororo.
Image taken with permission from Google Maps (Map data ©2017 Google).
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Dihydroartemisinin-piperaquine (DP) has demonstrated excellent efficacy for the treatment and prevention of malaria in Uganda. However, resistance to
both components of this regimen has emerged in Southeast Asia. The efficacy of
artemether-lumefantrine, the first-line regimen to treat malaria in Uganda, has also
been excellent, but continued pressure may select for parasites with decreased sensitivity to lumefantrine. To gain insight into current drug sensitivity patterns, ex vivo
sensitivities were assessed and genotypes previously associated with altered drug
sensitivity were characterized for 58 isolates collected in Tororo, Uganda, from subjects presenting in 2016 with malaria from the community or as part of a clinical
trial comparing DP chemoprevention regimens. Compared to community isolates,
those from trial subjects had lower sensitivities to the aminoquinolines chloroquine,
monodesethyl amodiaquine, and piperaquine and greater sensitivities to lumefantrine and mefloquine, an observation consistent with DP selection pressure. Compared to results for isolates from 2010 to 2013, the sensitivities of 2016 community
isolates to chloroquine, amodiaquine, and piperaquine improved (geometric mean
50% inhibitory concentrations [IC50] ! 248, 76.9, and 19.1 nM in 2010 to 2013 and
33.4, 14.9, and 7.5 nM in 2016, respectively [P " 0.001 for all comparisons]), the sensitivity to lumefantrine decreased (IC50 ! 3.0 nM in 2010 to 2013 and 5.4 nM in
2016 [P " 0.001]), and the sensitivity to dihydroartemisinin was unchanged (IC50 !
1.4 nM). These changes were accompanied by decreased prevalence of transporter
mutations associated with aminoquinoline resistance and low prevalence of polymorphisms recently associated with resistance to artemisinins or piperaquine. Antimalarial drug sensitivities are changing in Uganda, but novel genotypes associated
with DP treatment failure in Asia are not prevalent.
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W

ith widespread resistance to older drugs, the World Health Organization currently
recommends artemisinin-based combination therapies (ACTs) as first-line treatments for uncomplicated malaria in Africa, where ACTs remain highly efficacious
against Plasmodium falciparum, the most lethal and prevalent of the human malaria
species (1). ACTs combine a potent and fast acting artemisinin derivative with a longeracting partner drug, notably lumefantrine, piperaquine, amodiaquine, mefloquine, or
pyronaridine (2). Because the partner drugs circulate long after short-acting artemisinins have been cleared, resistance may be selected if patients are reinfected soon after
therapy.
For many years, malaria was treated principally with the aminoquinoline chloroquine. Resistance to chloroquine and its analogue amodiaquine is strongly associated
December 2017 Volume 61 Issue 12 e01516-17
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with mutations in two putative drug transporters: PfCRT 76T and PfMDR1 86Y and
1246Y. Treatment with chloroquine and amodiaquine selects for these same mutations
(3, 4). Until recently, nearly all P. falciparum strains isolated in Uganda demonstrated
chloroquine resistance, as evidenced by poor chloroquine treatment outcomes (5), high
ex vivo half-maximal inhibitory (IC50) values (6, 7), and the near universal prevalence of
the transporter mutations noted above (8). In 2004, Uganda established the ACT
artemether-lumefantrine (AL) as the national therapy for uncomplicated malaria; implementation was slow, but AL use is currently widespread, and it has demonstrated
excellent antimalarial efficacy (9, 10). AL selects for wild-type sequences at the same
alleles selected for mutations by aminoquinolines, and these wild-type sequences have
been associated with moderately decreased lumefantrine sensitivity (7, 11–13). Thus,
aminoquinolines and lumefantrine exert opposite selective pressures on P. falciparum
drug resistance mediators.
Although it is structurally related to chloroquine and amodiaquine, mediators of
resistance and selective effects of the bisquinoline piperaquine, a component of the
ACT dihydroartemisinin-piperaquine (DP), are less certain. In Africa, DP has shown
excellent efficacy for the treatment of malaria (14, 15) and for malaria chemoprevention
in children (16, 17) and pregnant women (18). For chemoprevention, DP benefits from
the long half-life of piperaquine, but the impacts of this regimen on the selection of
drug resistance are uncertain. Use of DP as therapy (19) or chemoprevention (20) was
not associated with selection of the pfcrt and pfmdr1 mutations selected by other
aminoquinolines in Burkina Faso, but in Uganda, DP treatment (12) and chemoprevention (7, 17) was followed by selection of parasites with increased prevalence of
aminoquinoline resistance-mediating mutations, although selection of different mutations varied among the studies.
Artemisinin resistance emerged in Southeast Asia over the last decade, manifesting
as delayed parasite clearance after therapy and causally linked to mutations in the k13
gene (PF3D7_1343700) (21–23). More recently, resistance to piperaquine also emerged
in Southeast Asia, linked to an increased plasmepsin 2 (PF3D7_1408000) copy number
(24, 25) and, in one study, an E415G mutation in an exonuclease (encoded by
PF3D7_1362500) (24). In the same region, amplification of the pfmdr1 gene has been
linked to decreased sensitivity to mefloquine and lumefantrine but increased sensitivity
to aminoquinolines (26, 27). However, pfmdr1 gene amplification appears to be very
uncommon in P. falciparum in Africa.
Considering recent changes in malaria treatment practices in Uganda, we investigated changes in drug sensitivity. We analyzed the drug susceptibility phenotypes and
genotypes of clinical P. falciparum isolates collected from two sources in 2016 and
compared them to the characteristics of isolates collected in prior years. We found
marked changes in drug susceptibilities over time that were consistent with decreased
selective pressure from chloroquine and/or increased selective pressure from the national
treatment regimen AL.
RESULTS
P. falciparum isolates. Isolates were collected from May to July 2016 from subjects
with uncomplicated malaria from two sources: 29 children and adults from the community (mean age, 4.7 years; range, 1 to 21 years) diagnosed at Tororo District Hospital
and 29 children (mean age, 1.4 years; range, 1.2 to 1.5 years) enrolled in a trial
comparing two different regimens of DP (monthly or every 3 months) for the prevention of malaria.
Comparative ex vivo drug sensitivities. We compared ex vivo drug sensitivities
between samples from community members and trial subjects. Samples from trial
subjects were significantly less sensitive to the aminoquinolines chloroquine, monodesethyl amodiaquine (the active metabolite of amodiaquine), and piperaquine; were
significantly more sensitive to lumefantrine and mefloquine; and had no difference in
sensitivity to dihydroartemisinin (DHA), atovaquone, or pyronaridine (Table 1). These
results were consistent with selection by DP in trial subjects for decreased aminoquinoDecember 2017 Volume 61 Issue 12 e01516-17
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TABLE 1 Ex vivo drug sensitivity of P. falciparum isolates collected from 2010 to 2013 and in 2016 from trial and community patientsa
P value
Source and/or
study period (yr)
Dd2
3D7
2010–2013
2016, trial
2016, community

No. of
samples
7
7
408
25
24

Geometric
mean IC50
(nM)
209
9.2
248
57.1
33.4

95% CI
(nM)
180–242
7.9–10.8
223–275
32.7–99.6
19.8–56.2

IC50 range
(nM)
155–240
6.7–11
31.0–1,400
12.4–727
8.7–318

2010 to 2013
vs 2016 trial

2010 to 2013
vs 2016
community

2016 trial vs
2016
community

!0.001

!0.001

!0.001

Dd2
3D7
2010–2013
2016, trial
2016, community

7
7
421
20
24

35.5
5.4
76.9
20.6
14.9

25.8–48.8
4.7–6.3
70.2–84.1
15.0–28.4
10.6–21.0

25–61
4.1–6.2
12.5–565
7.5–91.8
4.6–70.4

!0.001

!0.001

!0.001

Dd2
3D7
2010–2013
2016, trial
2016, community

7
7
381
25
25

4.4
3.7
19.1
8.6
7.5

2.6–7.3
2.6–5.2
17.1–21.4
6.5–11.2
6.0–9.3

1.8–9.6
2–6.4
3.1–189
1.8–26.6
2.7–20.5

!0.001

!0.001

0.05

Dd2
3D7
2010–2013
2016, trial
2016, community

7
7
378
24
25

1.8
3.4
3.0
3.4
5.4

1.4–2.4
3.0–3.7
2.6–3.3
2.6–4.5
4.3–6.9

1.3–2.7
2.7–3.7
0.4–24.4
0.6–11.6
1.8–23.7

0.52

!0.001

!0.001

Dd2
3D7
2010–2013
2016, trial
2016, community

7
7
442
25
24

0.8
0.9
1.4
1.7
1.4

0.5–1.3
0.6–1.5
1.3–1.5
1.4–2.2
1.2–1.7

0.5–2.1
0.6–2.2
0.3–16.9
0.5–4.4
0.4–3.9

0.52

0.94

0.55

Atovaquone

Dd2
3D7
2016, trial
2016, community

7
7
18
22

0.2
0.1
0.5
0.5

0.1–0.3
0.1–0.2
0.4–0.6
0.4–0.6

0.1–0.3
0.1–0.2
0.2–1.0
0.1–1.0

0.97

Mefloquine

Dd2
3D7
2016, trial
2016, community

7
7
20
24

10.2
9.0
18.8
21.2

7.2–14.4
6.9–11.6
15.6–22.8
18.5–24.4

6.7–20
6.4–14
5.9–33.6
8.9–41.7

!0.001

Pyronaridine

Dd2
3D7
2016, trial
2016, community

7
7
24
23

1.8
1.0
2.5
2.2

0.9–3.8
0.8–1.4
1.8–3.5
1.5–3.3

0.7–6.0
0.6–1.6
0.7–29.1
0.2–10.1

0.69

Drug
Chloroquine

Monodesethyl
amodiaquine

Piperaquine

Lumefantrine

Dihydroartemisinin

aGeometric

mean IC50s for each group were compared using t tests. Dd2 and 3D7 are laboratory control strains. Data from 2010 to 2013 were published previously (7).

line sensitivity in parasites that emerged despite chemoprevention. We then compared
results for samples collected in 2016 to those for samples collected at the same study
site from 2010 to 2013 (7). Parasites collected from the community in 2016 were more
sensitive to the tested aminoquinolines but less sensitive to lumefantrine than the
samples collected earlier (Table 1).
Because the standard 72-h IC50 assay does not identify DHA resistance in Southeast
Asian parasites (28), the ex vivo ring-stage survival assay, in which parasites are exposed
to a 6-h pulse of 700 nM DHA, was performed on 16 samples collected from the
community and 16 samples collected from trial subjects in 2016. Seven of the community samples had undetectable parasites at 72 h, and the remaining nine samples
had median parasitemia of 0.5% that of controls. For the trial samples, seven had
undetectable parasites at 72 h, and the remainder had median parasitemias that were
0.6% those of controls. Our results were similar to those for parasites collected in
December 2017 Volume 61 Issue 12 e01516-17

Table 1. Ex vivo drug sensitivity of P. falciparum isolates collected from 2010 to 2013 and in 2016 from trial and community patients.
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FIG 1 Representative piperaquine (PQ) growth inhibition curves for four different P. falciparum isolates
collected in 2016.

Kampala, Uganda, in 2014 (29) and contrasted with those for DHA-resistant parasites
from Southeast Asia, in which 72-h parasitemias were much higher (median 13.5% that
of controls in isolates from a region of Cambodia with frequent artemisinin resistance
[30]). Thus, we did not see evidence for ex vivo artemisinin resistance in Ugandan
parasites.
Piperaquine resistance in Southeast Asia has been accompanied by irregular doseresponse curves, necessitating establishment of novel methods for determining ex vivo
drug sensitivity (31). It was thus important to confirm reliable determination of piperaquine sensitivity by our methods. Standard 72-h growth inhibition assays yielded
sigmoidal dose-response curves that were reproducible and readily interpretable (Fig.
1). Thus, in contrast to the case for Southeast Asian isolates resistant to piperaquine,
standard IC50 determinations were deemed valid for the Ugandan isolates.
Polymorphisms in parasite drug resistance markers. Prevalences of polymorphisms
in putative transporters that are associated with sensitivity to a number of antimalarials
were compared between P. falciparum isolates from 2010 to 2013 and isolates from
2016. Consistent with previous trends (7, 8, 12, 32), genotypes have changed markedly
in recent years, with reversion to wild-type sequences at pfcrt K76T (P ! 0.001) and
pfmdr1 N86Y (P ! 0.01) and D1246Y (P " 0.095) (Fig. 2). Nonsignificant trends toward
greater prevalence of wild-type pfcrt K76 and pfmdr1 N86 sequences in community
compared to trial samples were also seen, an observation consistent with selective
pressure from DP in trial subjects. Sensitivity to some drugs is also altered by amplification of pfmdr1, but this phenomenon has been uncommon in African parasites. All 58
samples collected in 2016 had only one copy of pfmdr1.
Sequencing of the propeller-encoding domain of k13, where certain mutations are
strongly associated with artemisinin resistance in Southeast Asia, identified a singlenucleotide polymorphism (SNP) in 1 of 29 community samples that corresponded to an
A578S mutation and a mixed wild-type/A578S genotype in 1 of 27 trial samples. The
A578S mutation has been described in isolates from Uganda and other African countries, and it has not been associated with artemisinin resistance (29, 32, 33).
December 2017 Volume 61 Issue 12 e01516-17

Figure 4. Representative piperaquine growth inhibition curves for four different P. falciparum isolates collected in 2016.
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FIG 2 Allele prevalence over time. Wild-type, mixed, and mutant allele prevalences are indicated for the
2010 to 2013 trial and the 2016 trial and community samples. Univariate analysis using generalized
estimating equations with exchangeable correlations was used to determine significance of genotype
changes over time. Asterisks indicate significance of comparisons between wild-type and mixed/mutant
prevalences for the indicated samples (P ! 0.01 [**] and P ! 0.001 [***]). Allele prevalences from 2010 to
2013 were published previously (7).

Recent reports have identified amplification of a gene encoding plasmepsin 2 and
a SNP in an exonuclease gene (PF3D7_1362500) that encodes an E415G mutation as
markers of piperaquine resistance in Southeast Asia (24, 25). We assessed the prevalence of these polymorphisms in Ugandan parasites. First, we assessed the plasmepsin
2 (PF3D7_1408000) copy number in samples collected in 2010 to 2013, when piperaquine sensitivity varied more widely in Tororo (Table 1) (7), stratifying parasites with
piperaquine IC50s above or below 50 nM. Second, we assessed the plasmepsin 2 copy
number in samples collected in 2016. For all three sets of samples, we identified
increased copy number in 10 to 14% of samples, but there was no apparent association
between increased copy number and piperaquine sensitivity (Table 2). Third, we

TABLE 2 plasmepsin 2 copy number among samples collected from 2010 to 2013 and in
2016a
Sample period (yr)
2010–2013

n
36
22

PQ IC50 (nM)
!50
"50

No. of samples (%) with increased
plasmepsin 2 copy no.
4 (11.1)
3 (13.6)

2016, trial
2016, community

29
29

!50
!50

3 (10.3)
4 (13.8)

aThe

copy number was considered increased when measured at "1.6 copies. n, total number of samples;
PQ, piperaquine.
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FIG 3 Associations of ex vivo geometric mean IC50s with the indicated polymorphisms. “N” represents the number of samples with wild-type (wt), mixed (mix),
or mutant (mut) genotypes. The geometric mean IC50s for the wild-type genotype were compared to other genotypes using t tests, with the significance noted
(P ! 0.05 [*], P ! 0.01 [**], and P ! 0.001 [***]).

sequenced the exonuclease gene in 29 community samples and 27 trial samples
collected in 2016, as well as the same 58 samples from 2010 to 2013 for which we
assessed plasmepsin 2 copy number. The exonuclease E415G mutation was not seen in
any of the samples. However, two different SNPs were detected in the 2010 –2013
samples, and five different SNPs were detected in the 2016 samples. Five of the seven
polymorphisms were nonsynonymous, encoding (i) a D360E mutation (from 2012), (ii)
a Y365C mutation (2016 community), (iii) a V352A mutation (2016 trial), (iv) a set of
seven nonsynonymous SNPs (N369D, K371N, V372D, N373K, and N374V mutations;
2016 trial), and (v) a 24-base-pair insertion corresponding to 8 amino acids (DNDKVN
NN), starting at position 376 (2016 community).
Associations of ex vivo drug sensitivity with transporter polymorphisms. We
and others have previously shown that polymorphisms in the putative transporters
pfcrt and pfmdr1 are associated with altered ex vivo drug sensitivity (7, 12, 34–38). We
tested for associations between pfcrt K76T and pfmdr1 N86Y, Y184F, and D1246Y
polymorphisms, and the ex vivo drug sensitivities were determined for samples collected in 2016 (Fig. 3). Consistent with previous reports (7, 34, 35), decreased sensitivity
to chloroquine, monodesethyl amodiaquine, and pyronaridine and increased sensitivity
to lumefantrine and mefloquine were associated with the mutant pfcrt 76T and pfmdr1
86Y sequences (Fig. 3) (36). Interestingly, consistent with prior reports (7, 37), the
associations seen for other aminoquinolines were not seen for piperaquine. Associations with other polymorphisms and for other drugs were mostly not significant.
DISCUSSION
We characterized ex vivo drug sensitivities and molecular markers associated with
drug sensitivity for P. falciparum isolates collected in Tororo, Uganda, in 2016. Sensitivities to aminoquinolines and other components of standard ACTs differed between
isolates from the community and those receiving regular DP in a chemoprevention trial,
suggesting selective pressure of piperaquine for aminoquinoline resistance. More
notably, sensitivities to these drugs differed markedly compared to results for isolates
collected in 2010 to 2013 (7). Specifically, sensitivities to aminoquinolines have increased and sensitivity to lumefantrine has decreased, which is consistent with the
December 2017 Volume 61 Issue 12 e01516-17

Figure 6. Associations of ex vivo geometric mean IC50s with the indicated polymorphisms.
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selective pressure of AL, the national malaria treatment regimen. These changes were
accompanied by decreased prevalence of well-characterized transporter mutations
(PfCRT 76T, PfMDR1 86Y, and 1246Y) associated with aminoquinoline resistance but not
by an increased prevalence of polymorphisms recently associated with resistance to
artemisinins or piperaquine. Thus, antimalarial drug sensitivities are changing in
Uganda, most remarkably with reversion to aminoquinoline sensitivity, and genotypes
associated with ACT treatment failure in Asia are not prevalent.
Uganda changed from chloroquine-based regimens to AL for the treatment of
malaria, with implementation beginning in 2006 (39). Replacement of chloroquine by
other regimens has been followed by changes in drug sensitivity in other countries. In
Malawi, after discontinuation of chloroquine, the prevalence of the PfCRT 76T mutation,
which is the primary mediator of chloroquine resistance (38), decreased markedly (40),
followed by excellent treatment efficacy for chloroquine (41). In Uganda, ex vivo
evidence of chloroquine resistance (IC50 ! 50 to 100 nM) was common in isolates
collected from 2006 to 2008 in Kampala (6) and from 2010 to 2013 in Tororo (7),
findings consistent with a high prevalence of the PfCRT 76T mutation (3, 42). This
situation changed in Tororo most notably beginning in 2012, with increasing prevalence of the pfcrt K76 wild-type genotype and decreasing chloroquine ex vivo IC50s (7,
8). Our data from 2016 show that this trend has continued, with— based on both
parasitological and genetic assessments—the majority of parasites being sensitive to
chloroquine and amodiaquine. The replacement of aminoquinoline-resistant parasites
by sensitive parasites has been accompanied by reemergence of wild-type sequences
at pfmdr1 86 and 1246 and by decreases in the ex vivo sensitivity to lumefantrine.
However, the majority of malaria infections in Uganda are likely polyclonal. Minority
clones may persist, allowing rapid selection of parasites with altered sensitivity when
certain drugs are used, as seen in Malawi with the discontinuation of chloroquine (40)
and in Uganda where treatment with artesunate-amodiaquine or AL selected for
different genotypes in new infections emerging after therapy (43). The changes happening in Uganda have likely been driven by both decreased selective pressure from
chloroquine and increased selective pressure from lumefantrine.
For the aminoquinolines chloroquine and amodiaquine, resistance is linked to
mutations in pfcrt and, to a lesser extent, pfmdr1, and use of these drugs selects for the
same mutations (3, 4, 34, 35, 44). However, associations are less straightforward for the
related bisquinoline piperaquine. With the use of DP for the treatment or prevention of
malaria in Uganda, selection in parasites that emerged after therapy was consistently
seen for PfMDR1 86Y, but selection at other alleles was inconsistent (7, 12, 17). In the
present study, samples from the DP chemoprevention trial had decreased sensitivity to
chloroquine, monodesethyl amodiaquine, and piperaquine, increased sensitivity to
lumefantrine and mefloquine, and an increased prevalence of the PfCRT 76T and
PfMDR1 86Y mutations; all of these findings are consistent with a selective pressure of
piperaquine, as seen previously for chloroquine (38) and amodiaquine (4, 45). However,
in contrast to the results for chloroquine and amodiaquine, the ex vivo drug sensitivities
for piperaquine were not clearly linked to the prevalences of pfcrt and pfmdr1 polymorphisms (7; the present study). The reasons for the differences in results for different
aminoquinolines are uncertain; the larger size of piperaquine may lead to decreased
impact of transporter mutations on sensitivity to this drug. In any event, it appears that
the widespread use of DP for malaria chemoprevention will select for parasites with
decreased sensitivity to aminoquinolines but increased sensitivity to lumefantrine.
Of great concern is the identification of artemisinin resistance within the last decade
and of piperaquine resistance very recently in Southeast Asia (22, 24, 25, 46). Important
advances from groups in Asia have identified parasitological (30, 31) and molecular (21,
23–25) markers of resistance to these drugs which, when seen together, have been
accompanied by high rates of treatment failure with DP (31, 47). We utilized these new
tools to characterize parasites circulating in Tororo in 2016. As seen in prior studies from
Uganda, occasional k13 mutations were seen (12, 29, 33), but these were not the
mutations associated with artemisinin resistance in Southeast Asia, and prevalence was
December 2017 Volume 61 Issue 12 e01516-17
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not associated with drug sensitivity or recent drug pressure. In addition, as seen
recently in parasites from Kampala (29), the ex vivo DHA ring survival assay did not
suggest artemisinin resistance in Ugandan parasites. Similarly, an increase in plasmepsin
2 copy number, a newly identified marker associated with piperaquine resistance, was
also seen occasionally in Ugandan isolates, but it was not associated with piperaquine
sensitivity in recent isolates or in a comparison of older isolates with relatively high or
low piperaquine sensitivity. Overall, we did not see evidence suggesting that resistance
to artemisinins or piperaquine has emerged in Uganda.
Changes in antimalarial drug use have been accompanied by marked changes in the
drug sensitivity of malaria parasites around the world. Our new results demonstrate
marked recent changes in Ugandan parasites with, for the most part, a return to
sensitivity to chloroquine and amodiaquine. Parasites have also shown some loss of
sensitivity to lumefantrine, a component of the national treatment regimen, but it is
unlikely that this slight change, although statistically significant, will impact AL treatment efficacy. Considering markers for resistance to artemisinins and piperaquine, our
results are reassuring, without evidence for emergence of the worrisome ACT resistance
seen in southeast Asia. Resistance to different antimalarial regimens has developed
more slowly in Africa than in other regions, likely due to strong antimalarial immunity
in Africans living in high-transmission areas, and yet it is extremely important to limit
resistance spread. Our results are consistent with other recent studies in suggesting
that the continued use of AL to treat malaria and the institution of DP for chemoprevention will exert opposite selective resistance pressures and thus may offer an optimal
means for maintaining antimalarial treatment and chemopreventive efficacy while
limiting the spread of drug resistance.
MATERIALS AND METHODS
Sample collection. P. falciparum isolates were obtained from May to July 2016 from two sources in
Tororo, Uganda. First, children and adults presenting at the Tororo District Hospital outpatient clinic with
malaria (temperature ! 37.5°C axillary or history of fever in the previous 24 h and a positive Giemsastained blood smear for P. falciparum) and without signs of severe disease were enrolled after informed
consent. Second, children enrolled in a clinical trial (registered at ClinicalTrials.gov [NCT02163447])
comparing monthly versus every 3-month intermittent therapy with DP to prevent malaria provided
samples if they presented to the study clinic with uncomplicated malaria (defined as above). The studies
were approved by the Makerere University Research and Ethics Committee, the Uganda National Council
for Science and Technology, and the University of California, San Francisco Committee on Human
Research. All subjects were treated with AL after sample collection.
Sample collection and parasite culture. Blood was collected before therapy in a heparinized tube.
Parasitemia was determined with Giemsa-stained thin smears. Samples containing only P. falciparum and
with a parasitemia of !1% were selected for culture. Initiation of culture was performed as previously
described (6), with slight modifications. Briefly, blood was centrifuged, plasma and buffy coat were
removed, and the erythrocyte pellet was washed three times with RPMI 1640 medium prewarmed to
37°C. The pellet was resuspended in complete media (RPMI 1640 medium supplemented with 25 mM
HEPES, 0.2% NaHCO3, 0.1 mM hypoxanthine, 10 "g/ml gentamicin, and 0.5% AlbuMAX II serum
substitute) to produce a 50% hematocrit. Culture aliquots were spotted onto Whatman 3MM filter paper
for molecular studies.
Ex vivo determination of drug susceptibilities. Drug susceptibilities were assessed immediately or
from samples stored at 4°C for a maximum of 18 h. Drug sensitivities were determined for chloroquine
(Sigma-Aldrich), monodesethyl amodiaquine (BD Gentest), piperaquine (Jinan Jiaquan International
Trade Co., Ltd.), lumefantrine (Sigma-Aldrich), dihydroartemisinin (DHA; TCI Tokyo Chemical Industry),
mefloquine (Sigma-Aldrich), atovaquone (Sigma-Aldrich), and pyronaridine (Santa Cruz Biotechnology)
using a 72-h, 96-well microplate fluorescence assay with SYBR green I detection as described previously
(48). Drugs were validated by regular IC50 assessment with laboratory strains Dd2 and 3D7, which yielded
results similar to those seen previously (7). Drugs were prepared as 10 mM stocks in dimethyl sulfoxide
or water and stored at !20°C. For assays, fresh drug stocks were prepared in complete media by diluting
chloroquine to 20 "M; piperaquine, monodesethyl amodiaquine, and mefloquine to 4 "M; lumefantrine
to 0.8 "M; and dihydroartemisinin, atovaquone, and pyronaridine to 0.4 "M. Drugs were serially diluted
3-fold in complete medium in 96-well microplates, with inclusion of drug-free control wells, to final
volumes of 50 "l/well. Parasite culture was added for a total volume of 200 "l/well with a 0.2%
parasitemia at 2% hematocrit. Plates were maintained under a gas mixture of 5% CO2, 5% O2, and 90%
N2 for 72 h at 37°C in a modular incubator (Billups Rothenberg, Del Mar, CA). Plates were frozen at !80°C
and thawed, wells were mixed, and 100 "l from each well was transferred to a black 96-well plate
containing 100 "l/well SYBR green lysis buffer (20 mM Tris buffer, 5 mM EDTA, 0.008% saponin, 0.08%
Triton X-100, and 0.2 "l/ml SYBR green I). Plates were incubated for 1 h in the dark at room temperature,
and the fluorescence was measured with a FLUOstar Omega plate reader (BMG LabTech, Inc., Cary, NC;
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485-nm excitation/530-nm emission). IC50s were derived by plotting percent growth against log drug
concentration and fitting the data by variable slope, sigmoidal curve fit in Prism 6.0 (GraphPad Software,
San Diego, CA). DHA drug susceptibility was measured with an ex vivo ring stage survival assay as
previously described (29).
Characterization of parasite polymorphisms. Parasite DNA was extracted from filter paper blood
spots using Chelex-100, genes of interest were amplified with nested PCR, and polymorphisms in pfcrt
and pfmdr1 were evaluated using a ligase detection reaction-fluorescent microsphere assay, all as
previously described (12, 49). pfmdr1 copy number was determined in quadruplicate using a TaqMan
real-time PCR assay with 3D7 and Dd2 strain standards, as previously described (12, 50). The k13propeller-encoding domains (codons 440 to 726; PF3D7_1343700) (21) and an exonuclease gene
(PF3D7_1362500) (24) were amplified and sequenced using previously described methods and primers.
For the exonuclease gene, samples that failed the initial round of PCR were amplified using nested PCR
with sequencing primers as previously described (24). Sequences were aligned with the 3D7 sequence
(PlasmoDB.org) using MacVector v.15 (MacVector, Inc., Apex, NC). SNPs were confirmed by inspection of
individual chromatograms. The plasmepsin 2 copy number was quantified using a previously published
quantitative PCR method (25). Amplification of plasmepsin 2 was defined as !1.6 copies.
Statistical methods. Data analysis was performed using Stata v.14 (StataCorp LLC, College Station,
TX). Significant differences between ex vivo IC50s were characterized with t tests. Univariate analysis using
generalized estimating equations with exchangeable correlations was used to determine significance of
genotype changes over time. Associations between genotype and drug sensitivity were determined by
comparing wild-type and mixed/mutant genotypes using t tests. Differences were considered significant
at P values of !0.05.
Accession number(s). Nucleotide sequence data are available in the GenBank database under
accession numbers MF477020 to MF477187.

ACKNOWLEDGMENTS
This study was supported by grants from the National Institutes of Health (AI075045,
AI117001, AI093784, and T37MD003407). S.A.R. and R.A.C. acknowledge travel grants
from Dominican University of California.
We thank the participants in the Tororo studies, the participants’ parents and
guardians, the clinical study team, and our administrative staff. We are grateful for
Didier Menard and Benoit Witkowski for kindly sharing the plasmepsin 2 copy number
assay and to Jenny Legac for technical support.

REFERENCES
1. World Health Organization. 2015. Guidelines for the treatment of malaria, 3rd ed. World Health Organization, Geneva, Switzerland.
2. Nosten F, White NJ. 2007. Artemisinin-based combination treatment of
falciparum malaria. Am J Trop Med Hyg 77:181–192.
3. Dorsey G, Kamya MR, Singh A, Rosenthal PJ. 2001. Polymorphisms in the
Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to
chloroquine in Kampala, Uganda. J Infect Dis 183:1417–1420. https://doi
.org/10.1086/319865.
4. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ. 2007.
Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after
treatment with artesunate-amodiaquine in Uganda. Antimicrob Agents
Chemother 51:3023–3025. https://doi.org/10.1128/AAC.00012-07.
5. Dorsey G, Kamya MR, Ndeezi G, Babirye JN, Phares CR, Olson JE, Katabira
ET, Rosenthal PJ. 2000. Predictors of chloroquine treatment failure in
children and adults with falciparum malaria in Kampala, Uganda. Am J
Trop Med Hyg 62:686 – 692. https://doi.org/10.4269/ajtmh.2000.62.686.
6. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal
PJ. 2010. In vitro sensitivities of Plasmodium falciparum to different
antimalarial drugs in Uganda. Antimicrob Agents Chemother 54:
1200 –1206. https://doi.org/10.1128/AAC.01412-09.
7. Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, Kozak B, Bloome J, Okiring J, Kakuru A, Bigira V, Kapisi J, Legac
J, Gut J, Cooper RA, Kamya MR, Havlir DV, Dorsey G, Greenhouse B,
Nsobya SL, Rosenthal PJ. 2015. Impact of antimalarial treatment and
chemoprevention on the drug sensitivity of malaria parasites isolated
from Ugandan children. Antimicrob Agents Chemother 59:3018 –3030.
https://doi.org/10.1128/AAC.05141-14.
8. Mbogo GW, Nankoberanyi S, Tukwasibwe S, Baliraine FN, Nsobya SL,
Conrad MD, Arinaitwe E, Kamya M, Tappero J, Staedke SG, Dorsey G,
Greenhouse B, Rosenthal PJ. 2014. Temporal changes in prevalence of
molecular markers mediating antimalarial drug resistance in a high
malaria transmission setting in Uganda. Am J Trop Med Hyg 91:54 – 61.
https://doi.org/10.4269/ajtmh.13-0647.
December 2017 Volume 61 Issue 12 e01516-17

9. Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Greenhouse
B, Staedke SG, Kamya MR, Dorsey G, Rosenthal PJ. 2010. Incidence of
malaria and efficacy of combination antimalarial therapies over 4 years
in an urban cohort of Ugandan children. PLoS One 5:e11759. https://doi
.org/10.1371/journal.pone.0011759.
10. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, MaitekiSebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ. 2007. Combination
therapy for uncomplicated falciparum malaria in Ugandan children: a
randomized trial. JAMA 297:2210 –2219. https://doi.org/10.1001/jama
.297.20.2210.
11. Baliraine FN, Rosenthal PJ. 2011. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemetherlumefantrine in Uganda. J Infect Dis 204:1120 –1124. https://doi.org/10
.1093/infdis/jir486.
12. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V,
Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal
PJ. 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis 210:344 –353.
https://doi.org/10.1093/infdis/jiu141.
13. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP. 2005. In vivo selection of Plasmodium falciparum pfmdr1
86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis
191:1014 –1017. https://doi.org/10.1086/427997.
14. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG,
Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F,
Dorsey G. 2007. Artemether-lumefantrine versus dihydroartemisininpiperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials
2:e20. https://doi.org/10.1371/journal.pctr.0020020.
15. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB,
Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H. 2008.
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treataac.asm.org 9

20
Rasmussen et al.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

ing uncomplicated malaria: a randomized trial to guide policy in Uganda.
PLoS One 3:e2390. https://doi.org/10.1371/journal.pone.0002390.
Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya
MR, Dorsey G. 2014. Protective efficacy and safety of three antimalarial
regimens for the prevention of malaria in young Ugandan children: a
randomized controlled trial. PLoS Med 11:e1001689. https://doi.org/10
.1371/journal.pmed.1001689.
Nankabirwa JI, Conrad MD, Legac J, Tukwasibwe S, Tumwebaze P, Wandera
B, Brooker SJ, Staedke SG, Kamya MR, Nsobya SL, Dorsey G, Rosenthal PJ.
2016. Intermittent preventive treatment with dihydroartemisininpiperaquine in Ugandan schoolchildren selects for Plasmodium falciparum
transporter polymorphisms that modify drug sensitivity. Antimicrob Agents
Chemother 60:5649 –5654. https://doi.org/10.1128/AAC.00920-16.
Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opira B, Olwoch P, Ategeka J, Nayebare P, Clark TD, Feeney
ME, Charlebois ED, Rizzuto G, Muehlenbachs A, Havlir DV, Kamya MR,
Dorsey G. 2016. Dihydroartemisinin-piperaquine for the prevention of
malaria in pregnancy. N Engl J Med 374:928 –939. https://doi.org/10
.1056/NEJMoa1509150.
Some AF, Sere YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B,
Ouedraogo JB, Rosenthal PJ. 2010. Selection of known Plasmodium
falciparum resistance-mediating polymorphisms by artemetherlumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not
dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents
Chemother 54:1949 –1954. https://doi.org/10.1128/AAC.01413-09.
Some AF, Zongo I, Compaore YD, Sakande S, Nosten F, Ouedraogo JB,
Rosenthal PJ. 2014. Selection of drug resistance-mediating Plasmodium
falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother 58:3660 –3665.
https://doi.org/10.1128/AAC.02406-14.
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim
S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S,
Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto
O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F,
Mercereau-Puijalon O, Menard D. 2014. A molecular marker of
artemisinin-resistant Plasmodium falciparum malaria. Nature 505:50 –55.
https://doi.org/10.1038/nature12876.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng
S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K,
Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV,
Phu NH, et al. 2014. Spread of artemisinin resistance in Plasmodium
falciparum malaria. N Engl J Med 371:411– 423. https://doi.org/10.1056/
NEJMoa1314981.
Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani
AP, Dacheux M, Khim N, Zhang L, Lam S, Gregory PD, Urnov FD,
Mercereau-Puijalon O, Benoit-Vical F, Fairhurst RM, Menard D, Fidock DA.
2015. Drug resistance: K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 347:428 – 431.
https://doi.org/10.1126/science.1260867.
Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, AlmagroGarcia J, Neal AT, Sreng S, Suon S, Drury E, Jyothi D, Stalker J, Kwiatkowski DP, Fairhurst RM. 2017. Genetic markers associated with
dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet
Infect Dis 17:164 –173. https://doi.org/10.1016/S1473-3099(16)30409-1.
Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim
S, Ke S, Kloeung N, Eam R, Khean C, Ken M, Loch K, Bouillon A, Domergue
A, Ma L, Bouchier C, Leang R, Huy R, Nuel G, Barale JC, Legrand E,
Ringwald P, Fidock DA, Mercereau-Puijalon O, Ariey F, Menard D. 2017.
A surrogate marker of piperaquine-resistant Plasmodium falciparum
malaria: a phenotype-genotype association study. Lancet Infect Dis
17:174 –183. https://doi.org/10.1016/S1473-3099(16)30415-7.
Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L,
Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S. 2004.
Mefloquine resistance in Plasmodium falciparum and increased pfmdr1
gene copy number. Lancet 364:438 – 447. https://doi.org/10.1016/S0140
-6736(04)16767-6.
Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S,
Fidock DA. 2006. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 194:528 –535. https://doi
.org/10.1086/507115.

December 2017 Volume 61 Issue 12 e01516-17

Antimicrobial Agents and Chemotherapy

28. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S,
Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WR, Suon S,
Mercereau-Puijalon O, Fairhurst RM, Menard D. 2013. Novel phenotypic
assays for the detection of artemisinin-resistant Plasmodium falciparum
malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet
Infect Dis 13:1043–1049. https://doi.org/10.1016/S1473-3099(13)70252-4.
29. Cooper RA, Conrad MD, Watson QD, Huezo SJ, Ninsiima H, Tumwebaze
P, Nsobya SL, Rosenthal PJ. 2015. Lack of artemisinin resistance in
Plasmodium falciparum in Uganda based on parasitological and molecular assays. Antimicrob Agents Chemother 59:5061–5064. https://doi
.org/10.1128/AAC.00921-15.
30. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, Chy S, Duong S,
Leang R, Ringwald P, Dondorp AM, Tripura R, Benoit-Vical F, Berry A,
Gorgette O, Ariey F, Barale JC, Mercereau-Puijalon O, Menard D. 2013.
Reduced artemisinin susceptibility of Plasmodium falciparum ring stages
in western Cambodia. Antimicrob Agents Chemother 57:914 –923.
https://doi.org/10.1128/AAC.01868-12.
31. Duru V, Khim N, Leang R, Kim S, Domergue A, Kloeung N, Ke S, Chy S,
Eam R, Khean C, Loch K, Ken M, Lek D, Beghain J, Ariey F, Guerin PJ, Huy
R, Mercereau-Puijalon O, Witkowski B, Menard D. 2015. Plasmodium
falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in
novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med 13:305. https://doi.org/10.1186/s12916-015-0539-5.
32. Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhamyankaka E,
Asua V, Walakira A, Nankabirwa J, Yeka A, Staedke SG, Greenhouse B,
Nsobya SL, Kamya MR, Dorsey G, Rosenthal PJ. 2017. Changing antimalarial drug resistance patterns identified by surveillance at three sites in
Uganda. J Infect Dis 215:631– 635. https://doi.org/10.1093/infdis/jiw614.
33. Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO,
Greenwood BM, Tagbor H, Williams J, Bojang K, Njie F, Desai M,
Kariuki S, Gutman J, Mathanga DP, Martensson A, Ngasala B, Conrad
MD, Rosenthal PJ, Tshefu AK, Moormann AM, Vulule JM, Doumbo OK,
Ter Kuile FO, Meshnick SR, Bailey JA, Juliano JJ. 2015. Absence of
putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect
Dis 211:680 – 688. https://doi.org/10.1093/infdis/jiu467.
34. Dahlstrom S, Aubouy A, Maiga-Ascofare O, Faucher JF, Wakpo A, Ezinmegnon S, Massougbodji A, Houze P, Kendjo E, Deloron P, Le Bras J,
Houze S. 2014. Plasmodium falciparum polymorphisms associated with
ex vivo drug susceptibility and clinical effectiveness of artemisinin-based
combination therapies in Benin. Antimicrob Agents Chemother 58:1–10.
https://doi.org/10.1128/AAC.01790-12.
35. Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, Juma D,
Yeda R, Andagalu B, Wanja E, Kamau E, Schnabel D, Bulimo W, Waters
NC, Walsh DS, Johnson JD. 2013. The role of Pfmdr1 and Pfcrt in
changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.
PLoS One 8:e64299. https://doi.org/10.1371/journal.pone.0064299.
36. Madamet M, Briolant S, Amalvict R, Benoit N, Bouchiba H, Cren J,
Pradines B, French National Centre for Imported Malaria Study Group.
2016. The Plasmodium falciparum chloroquine resistance transporter is
associated with the ex vivo P. falciparum African parasite response to
pyronaridine. Parasit Vectors 9:77. https://doi.org/10.1186/s13071-016
-1358-z.
37. Pascual A, Madamet M, Bertaux L, Amalvict R, Benoit N, Travers D, Cren
J, Taudon N, Rogier C, Parzy D, Pradines B, French National Reference
Centre for Imported Malaria Study Group. 2013. In vitro piperaquine
susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene. Malar J 12:431. https://doi.org/10
.1186/1475-2875-12-431.
38. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y,
Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV.
2001. A molecular marker for chloroquine-resistant falciparum malaria. N
Engl J Med 344:257–263. https://doi.org/10.1056/NEJM200101253440403.
39. Sears D, Kigozi R, Mpimbaza A, Kakeeto S, Sserwanga A, Staedke SG,
Chang M, Kapella BK, Rubahika D, Kamya MR, Dorsey G. 2013. Antimalarial prescription practices among outpatients with laboratoryconfirmed malaria in the setting of a health facility-based sentinel site
surveillance system in Uganda. Malar J 12:252. https://doi.org/10.1186/
1475-2875-12-252.
40. Frosch AE, Laufer MK, Mathanga DP, Takala-Harrison S, Skarbinski J,
Claassen CW, Dzinjalamala FK, Plowe CV. 2014. Return of widespread
aac.asm.org 10

21
Changing Antimalarial Drug Sensitivities in Uganda

41.

42.

43.

44.

45.

46.

chloroquine-sensitive Plasmodium falciparum to Malawi. J Infect Dis
210:1110 –1114. https://doi.org/10.1093/infdis/jiu216.
Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK,
Takala SL, Taylor TE, Plowe CV. 2006. Return of chloroquine antimalarial
efficacy in Malawi. N Engl J Med 355:1959 –1966. https://doi.org/10
.1056/NEJMoa062032.
Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, Machekano R,
Dokomajilar C, Rosenthal PJ, Dorsey G. 2006. Geographic differences in
antimalarial drug efficacy in Uganda are explained by differences in
endemicity and not by known molecular markers of drug resistance. J
Infect Dis 193:978 –986. https://doi.org/10.1086/500951.
Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, Belay K,
Kapella BK, Chang MA, Kamya MR, Staedke SG, Dorsey G, Rosenthal PJ.
2016. Artesunate/amodiaquine versus artemether/lumefantrine for the
treatment of uncomplicated malaria in Uganda: a randomized trial. J
Infect Dis 213:1134 –1142. https://doi.org/10.1093/infdis/jiv551.
Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A. 2007.
Selection of pfmdr1 mutations after amodiaquine monotherapy and
amodiaquine plus artemisinin combination therapy in East Africa. Infect
Genet Evol 7:562–569. https://doi.org/10.1016/j.meegid.2007.03.005.
Nawaz F, Nsobya SL, Kiggundu M, Joloba M, Rosenthal PJ. 2009. Selection of parasites with diminished drug susceptibility by amodiaquinecontaining antimalarial regimens in Uganda. J Infect Dis 200:1650 –1657.
https://doi.org/10.1086/647988.
Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey
F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M,

December 2017 Volume 61 Issue 12 e01516-17

Antimicrobial Agents and Chemotherapy

47.

48.

49.

50.

Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day
NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in
Plasmodium falciparum malaria. N Engl J Med 361:455– 467. https://doi
.org/10.1056/NEJMoa0808859.
Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, Kim S,
Witkowski B, Duru V, Domergue A, Khim N, Ringwald P, Menard D.
2015. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia:
dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother 59:4719 – 4726. https://doi
.org/10.1128/AAC.00835-15.
Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. 2004. Simple
and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48:1803–1806.
https://doi.org/10.1128/AAC.48.5.1803-1806.2004.
LeClair NP, Conrad MD, Baliraine FN, Nsanzabana C, Nsobya SL,
Rosenthal PJ. 2013. Optimization of a ligase detection reactionfluorescent microsphere assay for characterization of resistancemediating polymorphisms in African samples of Plasmodium falciparum.
J Clin Microbiol 51:2564 –2570. https://doi.org/10.1128/JCM.00904-13.
Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O’Neil M,
Milhous W, Wirth DF, Oduola AM. 2009. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 53:888 – 895.
https://doi.org/10.1128/AAC.00968-08.

aac.asm.org 11

22

Concluding Remarks
The drugs used to treat uncomplicated falciparum malaria impact the drug
sensitivities and genotypes of the malaria parasites infecting humans. Our results from
Uganda show that sensitivity to the 4-aminoquinolines is returning while sensitivity to the
arylaminoalcohols has decreased. The decreased sensitivity to the arylaminoalcohols does
not appear to be clinically relevant. Importantly, there is no apparent resistance to ACTs.
Having potent and efficacious drugs is crucial, so it is important to continue parasite
surveillance efforts to track changing drug susceptibility and molecular markers of
resistance among field isolates. This information will help determine if current and past
drug therapies are becoming more or less potent over time, which will aid decision
making on what drug therapies should be used. Parasite surveillance is a key method to
managing the ever-present threat of antimalarial drug resistance.
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